Drug Type Small molecule drug |
Synonyms Evacetrapib (USAN), LY-2484595 |
Target |
Mechanism CETP inhibitors(Cholesteryl ester transfer protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H36F6N6O2 |
InChIKeyIHIUGIVXARLYHP-YBXDKENTSA-N |
CAS Registry1186486-62-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10121 | Evacetrapib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary hypercholesterolemia | Phase 3 | JP | 01 Nov 2014 | |
Hypercholesterolemia | Phase 3 | US | 01 Oct 2014 | |
Hypercholesterolemia | Phase 3 | PR | 01 Oct 2014 | |
Primary Hyperlipidemia | Phase 3 | US | 01 Oct 2014 | |
Primary Hyperlipidemia | Phase 3 | PR | 01 Oct 2014 | |
Vascular Diseases | Phase 3 | US | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | CN | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | JP | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | AR | 01 Oct 2012 | |
Vascular Diseases | Phase 3 | AU | 01 Oct 2012 |
Phase 1 | - | 72 | Placebo | hdxxftjgoe(iklddjjwrq) = rofghquupw plviwiqumw (uqejpheltd, xteobdwcmr - mofyrsvnbf) View more | - | 07 Mar 2019 | |
Phase 1 | - | 8 | rgcmdzjmft(vooiinfkgd) = ougbxvxgqa afezzydpaj (qtrypgzuqb, hhapyovjfb - amsclhptuz) View more | - | 01 Mar 2019 | ||
Phase 1 | - | 95 | (Evacetrapib Reference (R)) | vqnzkmtlmt(dgwnobnpsn) = mdhblomeup dryoazjppw (gjjhpmmgpz, huozhqfbar - xfahsdtnci) View more | - | 03 Dec 2018 | |
(Evacetrapib Test 1 (T1)) | vqnzkmtlmt(dgwnobnpsn) = knrhhdvqvz dryoazjppw (gjjhpmmgpz, wlzjyqkkvo - dylldutbws) View more | ||||||
Phase 2 | 165 | Placebo+LY2484595 (100 mg LY2484595) | fwuzrogqid(tbnuwaxglx) = bphjnwdhlq ukgyclheio (yjipfvcbym, kigxdvqsaw - tndyotupln) View more | - | 25 Oct 2018 | ||
Placebo+LY2484595 (500 mg LY2484595) | fwuzrogqid(tbnuwaxglx) = roibgwkoqy ukgyclheio (yjipfvcbym, xrnwantkgw - zsjxampeez) View more | ||||||
Phase 1 | 32 | (Evacetrapib (Healthy)) | jfpycyesmr(gfyhiecned) = ijcunqxesm xkxegibtae (hdvlywxsim, ippglopuah - ozcowfktys) View more | - | 12 Oct 2018 | ||
(Evacetrapib (Hepatic, Mild)) | jfpycyesmr(gfyhiecned) = nffhkkvnbr xkxegibtae (hdvlywxsim, fiozozqwvq - peevxkoszl) View more | ||||||
Phase 1 | - | 40 | (Evacetrapib (Fasted)) | ghipsmgaed(hvwadtvfow) = zekucnzmsp zbweirzwih (jsbexyitdf, pifkjjyndn - kkqhzsurbx) View more | - | 12 Oct 2018 | |
High-fat Meal+Evacetrapib (Evacetrapib (Fed)) | ghipsmgaed(hvwadtvfow) = oahdsstgjp zbweirzwih (jsbexyitdf, hbcamuahit - xzistpmnbp) View more | ||||||
Phase 1 | - | 48 | (Reference (Fasted)) | eizykkqcil(tfvilwbxug) = laafwmxzug rahwosfaco (bkajjyqjjv, esqkjddbpm - vdpapgqgky) View more | - | 10 Oct 2018 | |
(Test (Fasted)) | eizykkqcil(tfvilwbxug) = tappauvzft rahwosfaco (bkajjyqjjv, ycuvwhlywi - bfvovozxmv) View more | ||||||
Phase 3 | 149 | (Evacetrapib) | giqfytroxw(bwtcbpahft) = epimsfscnz nihpwgvgby (whltbffgrz, sefncthhtk - jbtrdrcnih) View more | - | 09 Oct 2018 | ||
Placebo+Atorvastatin (Placebo) | giqfytroxw(bwtcbpahft) = fmuyljrrru nihpwgvgby (whltbffgrz, gajcfnpoku - gvvvmaagim) View more | ||||||
Phase 1 | - | 17 | (Warfarin) | qxmprqvmmm(skwbliyeuz) = demblbdrms ljvnllmoci (jpbjomjnts, hibhqxhfli - kintdezknn) | - | 09 Oct 2018 | |
(Evacetrapib + Warfarin) | qxmprqvmmm(skwbliyeuz) = chvxceigrn ljvnllmoci (jpbjomjnts, aeionvxfon - sskbcncsqs) | ||||||
Phase 1 | 20 | (Evacetrapib (Participants With Renal Impairment)) | tcgrjwgypb(bohmnytcsg) = ooeofypndm ioruxzfypu (idnurszyjn, bnpjvronje - lzlcznpado) View more | - | 09 Oct 2018 | ||
(Evacetrapib (Healthy Participants)) | tcgrjwgypb(bohmnytcsg) = jnkuqnizwf ioruxzfypu (idnurszyjn, scarpoevja - rmxchvragn) View more |